Entero Therapeutics Total Liabilities

Entero Therapeutics (ENTO) currently reports a total liabilities of $18M as of June 2026. That compares with $30M in the prior-year period — down 38.4% year over year. Use the charts on this page to explore Entero Therapeutics's total liabilities history and peer comparisons.

Entero Therapeutics's total liabilities decreased from $30M to $18M — a 38.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Entero Therapeutics reported $18M in total liabilities as of June 2026. That compares with $30M in the prior-year period — down 38.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $18M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Entero Therapeutics, and consider following ENTO for alerts when major investors trade the stock.

Entero Therapeutics is classified in the Healthcare sector. On total liabilities, it currently shows $18M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ENTO with unrelated industries.